- Home
- WAFD vs IDYA Comparison
WAFD vs IDYA Comparison
Compare WAFD & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAFD
- IDYA
- Stock Information
- Founded
- WAFD 1917
- IDYA 2015
- Country
- WAFD United States
- IDYA United States
- Employees
- WAFD N/A
- IDYA N/A
- Industry
- WAFD Major Banks
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- WAFD Finance
- IDYA Health Care
- Exchange
- WAFD Nasdaq
- IDYA Nasdaq
- Market Cap
- WAFD 3.0B
- IDYA 2.6B
- IPO Year
- WAFD N/A
- IDYA 2019
- Fundamental
- Price
- WAFD $37.15
- IDYA $26.79
- Analyst Decision
- WAFD Hold
- IDYA Strong Buy
- Analyst Count
- WAFD 5
- IDYA 12
- Target Price
- WAFD $36.60
- IDYA $53.67
- AVG Volume (30 Days)
- WAFD 423.3K
- IDYA 937.1K
- Earning Date
- WAFD 01-14-2025
- IDYA 11-04-2024
- Dividend Yield
- WAFD 2.80%
- IDYA N/A
- EPS Growth
- WAFD N/A
- IDYA N/A
- EPS
- WAFD 2.50
- IDYA N/A
- Revenue
- WAFD $704,024,000.00
- IDYA $3,922,000.00
- Revenue This Year
- WAFD N/A
- IDYA N/A
- Revenue Next Year
- WAFD $12.61
- IDYA $158.10
- P/E Ratio
- WAFD $14.88
- IDYA N/A
- Revenue Growth
- WAFD 0.44
- IDYA N/A
- 52 Week Low
- WAFD $25.79
- IDYA $25.20
- 52 Week High
- WAFD $38.58
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- WAFD 58.71
- IDYA 38.49
- Support Level
- WAFD $35.34
- IDYA $25.20
- Resistance Level
- WAFD $38.41
- IDYA $32.67
- Average True Range (ATR)
- WAFD 1.06
- IDYA 1.41
- MACD
- WAFD 0.02
- IDYA -0.29
- Stochastic Oscillator
- WAFD 71.74
- IDYA 21.29
About WAFD WaFd Inc.
WaFd Inc is engaged in providing lending, depository, insurance and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Geographically It operates in Washington, Oregon, Arizona, Texas, Utah. New Mexico, Nevada, Idaho and others. WaFd Inc provides, Personal Banking, Business Banking, Commercial Banking and Home Loans.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.